Family

Effect of background methotrexate dose on tofacitinib efficacy in patients with PsA


Key clinical point: In patients with psoriatic arthritis (PsA), 5 mg tofacitinib twice a day showed numerically better response with background 15 mg methotrexate per week. A twice daily dose of 10 mg tofacitinib, however, showed better response with background 15 mg methotrexate per week.

Major finding: In the 5 mg tofacitinib group, 51.4% vs. 47.4% of patients receiving background 15 mg methotrexate per week vs. 15 mg per week achieved American College of Rheumatology (ACR20) response at 3 months. However, in the 10 mg tofacitinib group, 54.9% vs. 51.8% of patients receiving 15 mg methotrexate per week vs. 15 mg per week achieved ACR20. No new safety risks were identified.

Study details: Findings are from pooled, post hoc exploratory analysis of 2 phase 3 trials, OPAL Broaden and OPAL Beyond , including 556 patients with active PsA randomly assigned to tofacitinib (5 mg or 10 mg twice daily) or placebo, with stable methotrexate.

Disclosures: This study was funded by Pfizer. Some of the authors reported ties with various sources, including Pfizer. C Wang and L Takiya declared being employees and shareholders of Pfizer.

Source: Kivitz AJ et al. Clin Rheumatol. 2021 Sep 12. doi: 10.1007/s10067-021-05894-2.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *